Gelteq (GELS) Other Non-Current Assets (2025)
Gelteq's (GELS) quarterly Other Non-Current Assets came in at $60588.2 in Q2 2025.
Gelteq (GELS) Other Non-Current Assets (2025) Analysis & Trends
Gelteq's Other Non-Current Assets history runs 1 years deep, the most recent figure standing at $60588.2 for Q2 2025.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $60588.2 in Q2 2025; TTM through Jun 2025 was $60588.2, a N/A change from a year earlier, with the FY2025 full-year figure at $60588.2, changed N/A from the prior year.
- Other Non-Current Assets was little changed at $60588.2 in Q2 2025 per GELS's latest filing.
- Across five years, Other Non-Current Assets topped out at $60588.2 in Q2 2025 and bottomed at $60588.2 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Gelteq | 740.00 | -47,821.64 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 60,588.18 |